Dr. Mayer Fishman on New Treatment Combination for Patients with Metastatic Chemo-Refractory Urothelial Cancer

October 30, 2015
Mayer Fishman, MD, PhD

Mayer Fishman, MD, PhD, Medical Oncologist, Moffitt Cancer Center, talks about the phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).

Mayer Fishman, MD, PhD, Medical Oncologist, Moffitt Cancer Center, talks about the phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).

Fisherman says that in previous studies, the IL-2/T-cell receptor fusion protein has helped to clear out UC tumors by stimulating the white blood cells. He says the new treatment with gemcitabine and cisplatin adds an element of immune therapy on top of the regular chemotherapy.